Drug Trial Radar · NCT01147640
Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections
Last checked: Nov 20, 2026Latest source record: Oct 25, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
122
Actual
Start
Jun 25, 2010
Primary completion
Feb 20, 2011
Study completion Mar 25, 2011
Sponsor
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
- Sponsor type
- Industry
- First posted
- Jun 22, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2, multicenter, prospective, randomized, double-blind study of CXA-101/ tazobactam (1000/500 mg q8h) and metronidazole (500 mg q8h) IV infusion vs. meropenem IV infusion (1000 mg q8h) and a matching saline placebo (q8h) in the treatment of cIAI in adult subjects. Dose adjustments for subjects with mild renal impairment are not necessary and subjects with more severe degrees of renal failure are excluded.
Conditions
- Complicated Intra-abdominal Infection
Interventions
CXA-101/ tazobactam and metronidazoleDrug
CXA-101/tazobactam (1000/500 mg q8h) plus metronidazole (500 mg q8h) administered via IV infusion
meropenem plus saline placeboDrug
meropenem IV infusion (1000 mg q8h) plus a matching saline placebo (q8h) administered via IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Response of CXA 101/Tazobactam and Metronidazole at Test of Cure (TOC) Visit in the Microbiological Modified Intent to Treat (mMITT) Analysis PopulationTime frame: Test-of-Cure Visit (7-14 days after End of Therapy [EOT])
Locations
33 sites in 5 countries. Site status is shown where the registry gives one.
Pulmonary Consultants and Primary Care Physicians Medical Group, Inc.
Orange, California
Los Angeles Biomedical Research Institue at Harbor UCLA Medical Center
Torrance, California
University of Colorado Hospital
Aurora, Colorado
Christiana Care Health System
Newark, Delaware
Pensacola Research Consultants, Inc.
Pensacola, Florida
Henry Ford Hospital
Detroit, Michigan
South Jersey Infectious Disease
Somers Point, New Jersey
Metro Health Medical Center
Cleveland, Ohio
The Ohio State University
Columbus, Ohio
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
University of Tennessee Health Science Center
Memphis, Tennessee
Sanatorio Guemes
C.a.b.a., Argentina
Hospital Nuestra Señora de la Misericordia
Córdoba, Argentina
Hospital San Roque
Córdoba, Argentina
Hospital Central de Mendoza
Mendoza, Argentina
Hospital Dr. José María Cullen
Santa Fe, Argentina
Hospital San Martín
Paraná, Entre Ríos Province, Argentina
Ltd Ivane Javakhishvili Tbilisi State University Center
Tbilisi, Georgia
JSC K.Eristavi National Center of Experimental and Clinical Surgery
Tbilisi, Georgia
Ltd Vakhtang Bochorishvili Antiseptic Center
Tbilisi, Georgia
Tbilisi State Hospital #4
Tbilisi, Georgia
Federal State Institution
Moscow, Russia
State Moscow Healthcare
Moscow, Russia
State Healthcare Institution
Moscow, Russia
Municipal Healthcare Institution "City Clinical Hospital #2"
Novosibirsk, Russia
Regional State Healthcare
Novosibirsk, Russia
State Healthcare Institution
Saint Petersburg, Russia
State Educational Institution of Higher Professional Education
Saint Petersburg, Russia
Saint Petersburg State Healthcare Institution "City Hospital # 26"
Saint Petersburg, Russia
Clinical Hospital Centre Zvezdara
Belgrade, Serbia
Emergency Centre, Clinical Centre of Serbia
Belgrade, Serbia
Clincal Centre Nis
Niš, Serbia
Clinical Centre of Vojvodina
Novi Sad, Serbia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.